FDA Requests Additional Thelin Study In “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Encysive hopes to answer the agency’s questions without further clinical work, however.
You may also be interested in...
Encysive Avoids Additional Trials For Thelin NDA
The firm has submitted a complete response to a recent FDA “approvable” letter using existing data for the pulmonary arterial hypertension drug.
GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.